vs

Side-by-side financial comparison of NorthEast Community Bancorp, Inc. (NECB) and Silence Therapeutics plc (SLN). Click either name above to swap in a different company.

NorthEast Community Bancorp, Inc. is the larger business by last-quarter revenue ($26.4M vs $15.7M, roughly 1.7× Silence Therapeutics plc). NorthEast Community Bancorp, Inc. runs the higher net margin — 40.9% vs -14.7%, a 55.6% gap on every dollar of revenue.

NorthEast Community Bancorp, Inc. (MD) is a U.S.-based bank holding company operating primarily in the Mid-Atlantic region. It provides a comprehensive suite of consumer and commercial banking services, including deposit products, mortgage loans, small business financing, and wealth management solutions to individual and local enterprise clients.

Silence Therapeutics is a London-based pharmaceutical company formed in 1994. The company has pioneered the development of short-interfering ribonucleic acid (siRNA) therapeutics for the treatment of rare diseases. Silence Therapeutics has offices in London, New Jersey, and Berlin, with its corporate headquarters located in Hammersmith, London.

NECB vs SLN — Head-to-Head

Bigger by revenue
NECB
NECB
1.7× larger
NECB
$26.4M
$15.7M
SLN
Higher net margin
NECB
NECB
55.6% more per $
NECB
40.9%
-14.7%
SLN

Income Statement — Q4 FY2025 vs Q1 FY2024

Metric
NECB
NECB
SLN
SLN
Revenue
$26.4M
$15.7M
Net Profit
$10.8M
$-2.3M
Gross Margin
82.2%
Operating Margin
59.0%
-35.6%
Net Margin
40.9%
-14.7%
Revenue YoY
3.9%
Net Profit YoY
5.8%
EPS (diluted)
$0.78
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NECB
NECB
SLN
SLN
Q4 25
$26.4M
Q3 25
$27.0M
Q2 25
$25.9M
Q1 25
$25.5M
Q4 24
$25.4M
Q3 24
$27.6M
Q2 24
$27.0M
Q1 24
$25.5M
$15.7M
Net Profit
NECB
NECB
SLN
SLN
Q4 25
$10.8M
Q3 25
$11.9M
Q2 25
$11.2M
Q1 25
$10.6M
Q4 24
$10.2M
Q3 24
$12.7M
Q2 24
$12.8M
Q1 24
$11.4M
$-2.3M
Gross Margin
NECB
NECB
SLN
SLN
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
82.2%
Operating Margin
NECB
NECB
SLN
SLN
Q4 25
59.0%
Q3 25
61.6%
Q2 25
59.5%
Q1 25
57.4%
Q4 24
57.0%
Q3 24
63.6%
Q2 24
65.6%
Q1 24
62.7%
-35.6%
Net Margin
NECB
NECB
SLN
SLN
Q4 25
40.9%
Q3 25
44.0%
Q2 25
43.1%
Q1 25
41.4%
Q4 24
40.1%
Q3 24
45.9%
Q2 24
47.5%
Q1 24
44.5%
-14.7%
EPS (diluted)
NECB
NECB
SLN
SLN
Q4 25
$0.78
Q3 25
$0.87
Q2 25
$0.82
Q1 25
$0.78
Q4 24
$0.74
Q3 24
$0.95
Q2 24
$0.97
Q1 24
$0.86
$-0.02

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NECB
NECB
SLN
SLN
Cash + ST InvestmentsLiquidity on hand
$81.2M
Total DebtLower is stronger
$70.0M
Stockholders' EquityBook value
$351.7M
$156.8M
Total Assets
$2.1B
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NECB
NECB
SLN
SLN
Q4 25
$81.2M
Q3 25
$64.3M
Q2 25
$59.4M
Q1 25
$89.5M
Q4 24
$78.3M
Q3 24
$97.8M
Q2 24
$113.9M
Q1 24
$107.4M
Total Debt
NECB
NECB
SLN
SLN
Q4 25
$70.0M
Q3 25
$170.0M
Q2 25
$135.0M
Q1 25
Q4 24
Q3 24
$7.0M
Q2 24
$47.0M
Q1 24
$47.0M
Stockholders' Equity
NECB
NECB
SLN
SLN
Q4 25
$351.7M
Q3 25
$344.0M
Q2 25
$336.7M
Q1 25
$327.2M
Q4 24
$318.3M
Q3 24
$309.6M
Q2 24
$300.0M
Q1 24
$288.9M
$156.8M
Total Assets
NECB
NECB
SLN
SLN
Q4 25
$2.1B
Q3 25
$2.1B
Q2 25
$2.0B
Q1 25
$1.9B
Q4 24
$2.0B
Q3 24
$2.0B
Q2 24
$1.9B
Q1 24
$1.9B
Debt / Equity
NECB
NECB
SLN
SLN
Q4 25
0.20×
Q3 25
0.49×
Q2 25
0.40×
Q1 25
Q4 24
Q3 24
0.02×
Q2 24
0.16×
Q1 24
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NECB
NECB
SLN
SLN
Operating Cash FlowLast quarter
$52.6M
$-9.1M
Free Cash FlowOCF − Capex
$50.8M
FCF MarginFCF / Revenue
192.3%
Capex IntensityCapex / Revenue
6.6%
0.0%
Cash ConversionOCF / Net Profit
4.86×
TTM Free Cash FlowTrailing 4 quarters
$89.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NECB
NECB
SLN
SLN
Q4 25
$52.6M
Q3 25
$14.1M
Q2 25
$15.6M
Q1 25
$10.9M
Q4 24
$48.7M
Q3 24
$14.4M
Q2 24
$11.1M
Q1 24
$12.9M
$-9.1M
Free Cash Flow
NECB
NECB
SLN
SLN
Q4 25
$50.8M
Q3 25
$13.6M
Q2 25
$14.9M
Q1 25
$10.6M
Q4 24
$48.2M
Q3 24
$14.2M
Q2 24
$11.0M
Q1 24
$12.8M
FCF Margin
NECB
NECB
SLN
SLN
Q4 25
192.3%
Q3 25
50.5%
Q2 25
57.3%
Q1 25
41.4%
Q4 24
189.3%
Q3 24
51.5%
Q2 24
40.8%
Q1 24
50.3%
Capex Intensity
NECB
NECB
SLN
SLN
Q4 25
6.6%
Q3 25
1.6%
Q2 25
2.9%
Q1 25
1.5%
Q4 24
2.0%
Q3 24
0.6%
Q2 24
0.5%
Q1 24
0.3%
0.0%
Cash Conversion
NECB
NECB
SLN
SLN
Q4 25
4.86×
Q3 25
1.18×
Q2 25
1.40×
Q1 25
1.04×
Q4 24
4.77×
Q3 24
1.14×
Q2 24
0.87×
Q1 24
1.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons